220 related articles for article (PubMed ID: 24590651)
21. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
22. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
23. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
Saylor PJ
Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
25. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
[TBL] [Abstract][Full Text] [Related]
26. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
27. Management of bone metastases in patients with castration-resistant prostate cancer.
Cathomas R; Bajory Z; Bouzid M; El Ghoneimy A; Gillessen S; Goncalves F; Kacso G; Kramer G; Milecki P; Pacik D; Tantawy W; Lesniewski-Kmak K
Urol Int; 2014; 92(4):377-86. PubMed ID: 24802278
[TBL] [Abstract][Full Text] [Related]
28. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
29. Bone metastases and bone loss medical treatment in prostate cancer patients.
Safriadi F
Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
[TBL] [Abstract][Full Text] [Related]
30. Selective lymph node dissection for castration-resistant prostate cancer.
Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
32. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
33. Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer.
Divrik RT; Türkeri L; Şahin AF; Akdoğan B; Ateş F; Çal Ç; Baltacı S;
Urol Int; 2012; 88(1):25-33. PubMed ID: 22179324
[TBL] [Abstract][Full Text] [Related]
34. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
35. Laparoscopic radical prostatectomy in a cadaveric renal transplant patient: first case in Thailand and the authors first experience--a case report.
Saema A; Patcharatrakul S; Kongchareonsombat W
J Med Assoc Thai; 2013 May; 96(5):633-6. PubMed ID: 23745320
[TBL] [Abstract][Full Text] [Related]
36. Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
Khushalani NI
J Clin Oncol; 2018 Jun; 36(17):1649-1653. PubMed ID: 29389234
[TBL] [Abstract][Full Text] [Related]
37. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
38. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
39. A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?".
Bekelman JE
J Clin Oncol; 2018 Jun; 36(18):1780-1784. PubMed ID: 29718792
[TBL] [Abstract][Full Text] [Related]
40. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
Kirby R
Nat Clin Pract Urol; 2005 Jun; 2(6):304-8. PubMed ID: 16474813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
